Industry Advisory Board

Dr. Dani P. Bolognesi, Ph.D.

Dr. Bolognesi is a co-founder, and former Chief Scientific Officer, Vice Chairman and member of the Board of Directors of Trimeris Inc.  He played a major role in the company's development since its inception.  From 1999 to 2003, he served as Chief Executive Officer of Trimeris which successfully brought a novel HIV drug (Fuzeon) to market.


Currently, Dr. Bolognesi serves as CEO and Chairman of a new start-up company, b3 bio inc, which sources and develops promising early stage technologies in partnership with a major pharmaceutical company.


Dr. Bolognesi's long-standing scientific career spans three decades during which he has held a number of positions at Duke University including: James B. Duke Professor of Surgery, Professor of Microbiology/Immunology, Vice Chairman for Research and Development-Department of Surgery, and Director of the Duke University Center for AIDS Research.  While at Duke, Dr. Bolognesi and his research team contributed to the discovery of AZT (the first anti-HIV drug), identified the HIV protein targeted by fusion inhibitor drugs, and established a central laboratory that supported all HIV vaccine clinical trials sponsored by the National Institutes of Health.


Dr. Bolognesi holds a doctoral degree in virology from Duke University.


August 21, 2013

Regado Completes $55 Million IPO